The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell.

Epstein-Barr virus-infected B cells in vivo demonstrate three distinct patterns of latent gene expression, depending on the differentiation stage of the cell. Tonsillar naive B cells express the EBNA2-dependent lymphoblastoid phenotype, characteristic of direct infection. Germinal center centroblasts and centrocytes as well as tonsillar memory B cells express a more restricted pattern of latent genes (EBNA1(Q-K)+, LMP1+, LMP2+, EBNA2-) that has only been seen previously in EBV-positive tumors. Peripheral memory cells express an even more restricted pattern where no latent genes are expressed, with the possible exception of LMP2. These results are consistent with a model where EBV uses the normal biology of B lymphocytes to gain access to and persist within the long-lived memory B cell compartment.

[1]  N. Raab-Traub,et al.  Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. , 1999, Science.

[2]  C. Meijer,et al.  Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. , 1996, Journal of clinical pathology.

[3]  J. Strominger,et al.  Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Whyte,et al.  Immunology of the tonsils. , 1998, Immunology today.

[5]  K. Rajewsky,et al.  The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. , 1998, Annual review of immunology.

[6]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[7]  K. Rajewsky,et al.  In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death , 1997, Cell.

[8]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[9]  S. Burrows,et al.  Copyright � 1995, American Society for Microbiology Immune Regulation in Epstein-Barr Virus-Associated Diseases , 2022 .

[10]  S. Modrow,et al.  Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus , 1995, Journal of virology.

[11]  D. Rowe,et al.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes , 1992, Journal of virology.

[12]  D. Thorley-Lawson,et al.  Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals , 1996, Journal of virology.

[13]  I. Ernberg,et al.  Epstein-Barr virus: adaptation to a life within the immune system. , 1994, Trends in microbiology.

[14]  S. T. Liu,et al.  Identification of a novel promoter located within the Bam HI Q region of the Epstein-Barr virus genome for the EBNA 1 gene. , 1995, DNA and cell biology.

[15]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule , 1997, The EMBO journal.

[16]  R. Freeman,et al.  Epstein-Barr Virus–Infected Resting Memory B Cells, Not Proliferating Lymphoblasts, Accumulate in the Peripheral Blood of Immunosuppressed Patients , 1999, The Journal of experimental medicine.

[17]  J. D. Capra,et al.  Analysis of somatic mutation in five B cell subsets of human tonsil , 1994, The Journal of experimental medicine.

[18]  D. Thorley-Lawson,et al.  Epstein-Barr virus and the B cell: that's all it takes. , 1996, Trends in microbiology.

[19]  S. Hamilton-Dutoit,et al.  Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease , 1991, The Lancet.

[20]  C. Arpin,et al.  Germinal center development , 1997, Immunological reviews.

[21]  J. Sample,et al.  Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein , 1996, Journal of virology.

[22]  E. Kremmer,et al.  Immunohistochemical Detection of the Epstein-Barr Virus–Encoded Latent Membrane Protein 2A in Hodgkin's Disease and Infectious Mononucleosis , 1997 .

[23]  A. Rickinson.  Epstein-Barr virus. , 2001, Virus research.

[24]  D. Thorley-Lawson,et al.  A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. , 1999, Life sciences.

[25]  D. Gray,et al.  B‐T Lymphocyte Interactions in the Generation and Survival of Memory Cells , 1996, Immunological reviews.

[26]  K. Rajewsky,et al.  EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. , 2000, Immunity.

[27]  D. Thorley-Lawson,et al.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell , 1997 .

[28]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[29]  E. Kieff,et al.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development , 1992, The Journal of experimental medicine.

[30]  E. Kieff.  Epstein-Barr virus and its replication , 1996 .

[31]  D. Gray,et al.  T cell memory is short-lived in the absence of antigen , 1988, Nature.

[32]  D. Thorley-Lawson,et al.  Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo , 1982, Journal of virology.